Evidence map›Paper›PMID 39791861›Full record

ArticleJournal of comparative effectiveness research2025

Cost-effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain.

Ruth Álvarez Cabellos, Jon Cacicedo, Susana Redondo Capafons, Heidi De Los Santos Real, Miriam Brines Julián, Darío Rubio-Rodríguez, Carlos Rubio-Terrés

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of comparative effectiveness research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ruth Álvarez CabellosMedical Oncology Department, Virgen de la Salud University Hospital, Avda. De Barber, 30, 45005, Toledo, Spain.
Jon CacicedoRadiation Oncology Department, Cruces University Hospital/Instituto de Investigación Biobizkaia, Pza. Cruces, s/n, 48903, Baracaldo, Spain.
Susana Redondo CapafonsParc Taulí University Hospital, Pharmacy Department, Parc Taulí 1, 08208, Sabadell, Spain.
Heidi De Los Santos RealMerck, SLU, C/María de Molina, 40, 28006, Madrid, Spain, an affiliate of Merck KGaA.
Miriam Brines JuliánMerck, SLU, C/María de Molina, 40, 28006, Madrid, Spain, an affiliate of Merck KGaA.
Darío Rubio-RodríguezHealth Value, HE Department, C/Virgen de Aránzazu, 21, 28034, Madrid, Spain.
Carlos Rubio-TerrésHealth Value, HE Department, C/Virgen de Aránzazu, 21, 28034, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Agents, ImmunologicalCetuximabChemoradiotherapyHead and Neck NeoplasmsCost-Benefit AnalysisHumansMarkov ChainsMonte Carlo MethodQuality-Adjusted Life YearsSpainAntineoplastic Agents, ImmunologicalCetuximabcetuximabcost–effectivenesslocally advanced head and neck cancerradiotherapySpain

Identifiers

PMID39791861
PMCPMC11773860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.